ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables grows, but more slowly than its trailing trend
Q1 FY2026 accounts payables of $2.81M rose 382.3% year over year, behind the +2029.8% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at -8.6% a year.
Context
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +382.3% toward the trailing-twelve-month pace of +2029.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.14M USD
- Year-over-year change
- +385.1%
- 4-year CAGR
- +64.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.14M | +385.1% |
| FY2024 | 2024-12-31 | (751K) | -154.5% |
| FY2023 | 2023-12-31 | 1.38M | -50.7% |
| FY2022 | 2022-12-31 | 2.8M | +855.6% |
| FY2021 | 2021-12-31 | 293K | — |
Accounts Payables vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 accounts payables of $4.37M is the 4th largest of the 11 companies compared; the peer median is $569.5K.
- Its year-over-year change of +2029.8% is the highest of 10, against a peer median of -69.6%.
- Over three fiscal years its annual growth of -8.6% compares with a peer median of +2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $16.33M | +57.3% | — | 3.6% | |
| LTM Jun 2026 | $16.07M | -193.4% | — | 9.5% | |
| LTM Jul 2026 | $8.01M | -69.6% | — | 0.3% | |
| LTM Mar 2026 | $4.37M | +2029.8% | -8.6% | — | |
| LTM Mar 2026 | $3.02M | -73.7% | +13.1% | 1.3% | |
| LTM Mar 2026 | $2.14M | +172.8% | -54.3% | 0.9% | |
| LTM Mar 2026 | $1.2M | — | — | — | |
| LTM Sep 2026 | $798K | +27.9% | -8.8% | — | |
| LTM Mar 2026 | $448K | +36.6% | +70.0% | — | |
| LTM Mar 2026 | $341K | -76.2% | +15.4% | — | |
| LTM Jun 2025 | $0 | -100.0% | -53.4% | 0.0% | |
| Peer median (excluding AVBP) | $569.5K | -69.6% | +2.2% | 1.1% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.